The evolving role of 18F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma

European journal of Clinical and Medical Oncology

Volumn 2, Issue 1, 2010, Pages

  Hosein, Peter J ^a   Lossos, Izidore S ^a,b  

^a Division of Hematology/Oncology   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Lymphoma; Positron emission tomography (PET); Rituximab

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RITUXIMAB;

CANCER EPIDEMIOLOGY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; FALSE POSITIVE RESULT; HUMAN; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 77956272043     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
4. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
5. Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17:1244-1253.
6. Fuks JZ, Aisner J, Wiernik PH. Restaging laparotomy in the management of the non-Hodgkin lymphomas. Med Ped Oncol. 1982;10:429-438.
7. Surbone A, Longo DL, DeVita VT Jr, et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832-1837.
8. Newman JS, Francis JR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 1994;190:111-116.
9. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy- D-glucose positron emission tomography in the detection and staging of malignant lymphoma: a bicenter trial. Cancer. 2001;91:889-899.
10. Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluoro-Dglucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104:1066-1074.
11. 18F-FDG) for the staging of low grade non-Hodgkin's lymphoma (NHL). Ann Oncol. 2001;12:825-830.
12. Pakos EE, Fotopoulos AD, Ioannidis JP. 18FFDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46: 958-963.
13. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110:3507-3516.
14. 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun. 1999;20:13-20.
15. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
16. Horning SJ, Juweid ME, Schoder H, et al. Interim Positron emission tomography (PET) in diffuse large B-cell lymphoma: independent expert nuclear medicine evaluation of ECOG 3404 (ASH Annual Meeting Abstracts). Blood. 2008;112:372.
17. Clinical Trials Broadcast: CALGB 50303 and CTSU 50. Clin Adv Hematol Oncol. 2006;4:848-850.
18. DeWit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 1997;8:S57(Suppl 1).
19. Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429-433.
20. Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1181-1184.
21. Mikhaeel NG, Timothy AR, O'Doherty MJ, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma-comparison with CT. Leuk Lymphoma. 2000;39:543-553.
22. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19:414-419.
23. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med. 2004;45:1796-1803.
24. Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
25. Mikosch P, Gallowitsch HJ, Zinke-Cerwenka W, et al. Accuracy of wholebody 18F-FDP-PET for restaging malignant lymphoma. Acta Med Austriaca. 2003;30:41-47.
26. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91:850-854.
27. 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDGPET? Ann Oncol. 2005;16:1524-1529.
28. Juweid ME, Wiseman GA, Vose JM, et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2005;23:4652-4661.
29. Han HS, Escalón MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol. 2009; 20:309-318.
30. Spaepen K, Stroobants S, Dupont P, et al. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur J Nucl Med Mol Imaging. 2003;30: 682-688.
31. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica. 2000;85:613-618.
32. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13: 1356-1363.
33. Mikhaeel NG, Hutchings M, Fields PA, et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non- Hodgkin lymphoma. Ann Oncol. 2005;16:1514-1523.
34. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106: 1376-1381.
35. Querellou S, Valette F, Bodet-Milin C, et al. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease. Ann Hematol. 2006;85:759-767.
36. Fruchart C, Reman O, Le Stang N, et al. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leuk Lymphoma. 2006;47:2547-2557.
37. Ng AP, Wirth A, Seymour JF, et al. Early therapeutic response assessment by (18)FDGpositron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma. 2007;48:596-600.
38. Cashen A, Dehdashti F, Luo J, Bartlett NL. Poor predictive value of FDGPET/ CT performed after 2 cycles of R-CHOP in patients with diffuse large B-Cell lymphoma (DLCL) (ASH Annual Meeting Abstracts). Blood. 2008; 112:371.
39. Pregno P, Chiappella A, Bello M, et al. Mid-treatment 18-FDG-positron emission tomography/computed tomography (PET) does not impact the outcome in patients with aggressive non Hodgkin lymphoma (NHL) (ASH Annual Meeting Abstracts). Blood. 2008;112:5295.
40. Gigli F, Nassi L, Negri M, et al. Interim 18f[FDG] positron emission tomography in patients with diffuse large B-cell lymphoma (ASH Annual Meeting Abstracts). Blood. 2008;112:3607.
41. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20:503-507.
42. Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009; 15:242-248.
43. Moskowitz C, Hamlin PA, Horwitz SM, et al. Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL (ASH Annual Meeting Abstracts). Blood. 2006;108:532.
44. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
45. Weeks JC, Yeap BY, Canellos GP, et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991;9:1196-1203.
46. Oh YK, Ha CS, Samuels BI, et al. Stages I-III follicular lymphoma: role of CT of the abdomen and pelvis in follow-up studies. Radiology. 1999;210: 483-486.
47. Foltz LM, Song KW, Connors JM. Who actually detects relapse in Hodgkin lymphoma: patient or physician (Annual meeting abstracts). Blood. 2004;104:853a-854a.
48. Liedtke M, Hamlin PA, Moskowitz CH, et al. Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population. Ann Oncol. 2006;17:909-913.
49. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol. 2003;14:123-130.
50. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27:1781-1787.
51. Cheson B. The case against heavy PETing. J Clin Oncol. 2009;27:1742-1743.
52. Kalkanis D, Stefanovic A, Paes F, Escalon MP, Serafini A, Lossos IS. [18F]- Fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximabcontaining chemotherapy. Leuk Lymphoma. 2009;50:904-911.